Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Argenx Se ADR (NQ: ARGX )

388.34 +5.84 (+1.53%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 167,283
Open 387.24
Bid (Size) 387.55 (3)
Ask (Size) 388.54 (9)
Prev. Close 382.50
Today's Range 384.65 - 389.82
52wk Range 327.73 - 550.76
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
From argenx SE
Via GlobeNewswire
After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay
Immunovant, which jumped Wednesday on news from rival Biohaven, reversed course Thursday. 
Via Investor's Business Daily

Performance

YTD
+1.93%
+1.93%
1 Month
+8.03%
+8.03%
3 Month
+1.72%
+1.72%
6 Month
-15.85%
-15.85%
1 Year
-1.94%
-1.94%

More News

Read More
Biohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage Study
Via Benzinga
Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump
Via Investor's Business Daily
Breaking Down argenx: 12 Analysts Share Their Views
Via Benzinga
Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
The Analyst Verdict: argenx In The Eyes Of 12 Experts
Via Benzinga
Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
ARGX Stock Earnings: argenx Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Exact Sciences Reports Q1 Loss, Joins Beyond Meat, Duolingo And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Key Takeaways From argenx Analyst Ratings
Via Benzinga
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
argenx announces results of Annual General Meeting of Shareholders
From argenx SE
Via GlobeNewswire
argenx to Present at BofA Securities 2024 Health Care Conference
From argenx SE
Via GlobeNewswire
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
From argenx SE
Via GlobeNewswire
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
From argenx SE
Via GlobeNewswire
Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy
Via Benzinga
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
From argenx SE
Via GlobeNewswire
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
From argenx SE
Via GlobeNewswire
Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
From argenx SE
Via GlobeNewswire
Guess? Posts Upbeat Earnings, Joins Lufax, Nortech Systems And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is European Pharma Giant Argenx Valued At Over $20B Trading Higher On Thursday?
Via Benzinga
Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.